Passage Bio
PASG
30 hedge funds and large institutions have $18.6M invested in Passage Bio in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.
40% more capital invested
Capital invested by funds: $13.2M → $18.6M (+$5.36M)
2.25% less ownership
Funds ownership: 51.87% → 49.62% (-2.2%)
6% less funds holding
Funds holding: 32 → 30 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$1.09M |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$296K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$123K |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$109K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$602K |
| 2 |
O
OrbiMed
New York
|
-$474K |
| 3 |
EAM
Erste Asset Management
Vienna,
Austria
|
-$324K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$167K |
| 5 |
Squarepoint
New York
|
-$110K |
PASG Hedge Fund Activity: Q4 2025 in Review
30 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2025, worth a combined $18.6M — up 40% from $13.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PASG and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Eversept Partners, opening a new position worth an estimated $1.09M. The largest seller was Tang Capital Management, exiting entirely with an estimated $602K sold.
- 30 institutional investors held Passage Bio (PASG) as of Q4 2025, down from 32 in Q3 2025.
- Funds reported $18.6M of Passage Bio stock for Q4 2025, up 40% quarter-over-quarter.
- 6 funds opened new Passage Bio positions in Q4 2025 and 7 closed out, a net change of -1 holder.
- The largest Passage Bio buyer in Q4 2025 was Eversept Partners, an estimated $1.09M added.
- The largest Passage Bio seller in Q4 2025 was Tang Capital Management, an estimated $602K sold.
Based on aggregated 13F filings for Q4 2025.